Mea Kākau: Robert Simon
Lā O Ka Hana: 22 Iune 2021
HōʻAno Hou I Ka Lā: 1 Iulai 2024
Anonim
DON’T CALL DEMONS AT NIGHT OR IT WILL END ...
Wikiō: DON’T CALL DEMONS AT NIGHT OR IT WILL END ...

Anter

Ua aʻo nui nā mea noiʻi i nā makahiki i hala aku nei e pili ana i ka psoriasis a me ke kuleana o ka ʻōnaehana pale pale i kēia ʻano. Ua alakaʻi kēia mau ʻike hou i kahi ʻoi aku ka palekana, ʻoi aku ka māka ʻia, a me nā lāʻau ʻoi aku ka maikaʻi o ka lāʻau psoriasis.

ʻOiai nā therapies a pau i loaʻa, hōʻike nā noiʻi he nui nā poʻe e loaʻa ana i ka lāʻau no ka psoriasis e hōʻoluʻolu ʻole i kā lākou lapaʻau ʻana a i ʻole ʻoluʻolu haʻahaʻa wale nō.

Inā ʻoe e ʻimi ana e hoʻololi i nā mālama ʻana no ka mea ʻaʻohe hopena o kāu mea i kēia manawa a i ʻole ke loaʻa nei nā hopena ʻaoʻao, maikaʻi ke aʻo e like me ka hiki e pili ana i nā koho hou loa.

ʻO nā biologics hou

Hana ʻia nā biologics mai nā mea i loaʻa i nā mea ola, e like me nā protein, nā sugars, a i ʻole nā ​​nucleic acid. I ka manawa ma ke kino, pale kēia mau lāʻau i kahi ʻāpana o ka ʻōnaehana pale pale i hāʻawi i kāu mau hōʻailona psoriasis.

Hoʻopilikia ʻo Biologics i kēia mau mea:

  • ʻōiwi tumrosis factor alpha (TNF-alpha), he protein ia e paipai ai i ka palaho i loko o ke kino
  • Nā pūnaewele T, ʻo ia nā hunaola keokeo
  • interleukins, ʻo ia nā cytokine (nā protein proteins liʻiliʻi) i pili i ka psoriasis

Kōkua kēia kūpale i ka maʻalahi.


Risankizumab-rzaa (Skyrizi)

Ua ʻae ʻia ʻo Risankizumab-rzaa (Skyrizi) e ka Food and Drug Administration (FDA) i ʻApelila 2019.

Hoʻolālā ʻia ia no ka poʻe me ka psoriasis kaulike a paʻakikī hoʻi nā moho no ka phototherapy (light therapy) a i ʻole ka systemic (body-wide) therapy.

Hana ʻo Skyrizi ma ka pale ʻana i ka hana o interleukin-23 (IL-23).

ʻO kēlā me kēia mahele lāʻau he ʻelua subcutaneous (ma lalo o ka ʻili) injection. Hoʻokaʻawale ʻia nā mahele hope ʻelua ma kahi o 4 mau pule kaawale. Hāʻawi ʻia ke koena i hoʻokahi manawa i kēlā me kēia 3 mahina.

ʻO nā hopena ʻē aʻe o Skyrizi:

  • luna maʻi hanu maʻi
  • nā hopena ma ka pūnaewele injection
  • ʻeha poʻo
  • luhi
  • nā maʻi lele

ʻO Certolizumab pegol (Cimzia)

Ua ʻae ka FDA i ka certolizumab pegol (Cimzia) ma ke ʻano he lapaʻau psoriasis i Mei 2018. Ua ʻae ʻia ia e mālama i nā ʻano e like me ka maʻi o Crohn a me psoriatic arthritis (PsA).

Mālama ʻo Cimzia i ka kaulike a koʻikoʻi i ka plake psoriasis i ka poʻe i moho no ka phototherapy a i ʻole ka systemic therapy. Hana ia ma ke kālailai ʻana i ka protein TNF-alpha.


Hāʻawi ʻia ka lāʻau lapaʻau ma ke ʻano he ʻelua subcutaneous injection i kēlā me kēia pule.

ʻO nā hopena ʻaoʻao maʻamau o Cimzia:

  • nā maʻi maʻi hanu o luna
  • hūwī
  • nā maʻi maʻi urinary tract (UTIs)

Tildrakizumab-asmn (Ilumya)

Ua ʻae ʻia ʻo Tildrakizumab-asmn (Ilumya) i loko o Malaki 2018. Hoʻohana ʻia ia e mālama i ka plake psoriasis i nā mākua i moho no ka phototherapy a i ʻole systemic therapy.

Hana ka lāʻau ma ke kāpae ʻana iā IL-23.

Hāʻawi ʻia ʻo Ilumya ma ke ʻano he inikua subcutaneus. ʻO nā injection ʻelua i hoʻokaʻawale ʻia i 4 mau pule kaawale. Mai ia manawa, hāʻawi ʻia nā injection i 3 mau mahina kaawale.

ʻO nā hopena ʻē aʻe o Ilumya:

  • nā hopena ma ka pūnaewele injection
  • luna maʻi hanu maʻi
  • pāhoehoe

ʻO Guselkumab (Tremfya)

Ua ʻae ʻia ʻo Guselkumab (Tremfya) i ka lā Iulai Iulai 2017. Hoʻohana ʻia ia e mālama i ka psoriasis kaulike a paʻakikī i nā poʻe i moho pū ʻia no ka phototherapy a me ka therapy systemic.

ʻO Tremfya ka biologic mua i hoʻokumu i ka IL-23.


Hāʻawi ʻia nā kōkō hoʻomaka mua ʻelua i 4 mau pule kaawale. Ma hope, hāʻawi ʻia ʻo Tremfya ma ke ʻano he subcutaneous injection i kēlā me kēia 8 pule.

ʻO nā hopena ʻaoʻao maʻamau e pili pū me:

  • ʻeha poʻo
  • luna maʻi hanu maʻi
  • nā hopena ma ka pūnaewele injection
  • ʻeha pū
  • pāhoehoe
  • maʻi ʻōpū

Brodalumab (Siliq)

Ua ʻae ʻia ʻo Brodalumab (Siliq) e ʻApelila i ka lā Pepeluali 2017. No nā poʻe e kū ana i nā pae hoʻohālikelike aʻe:

  • loaʻa ka pākēneka a koʻikoʻi psoriasis plake
  • he moho no ka phototherapy a i ʻole ka systemic therapy
  • ʻaʻole pane kā lākou psoriasis i nā ʻōnaehana ʻōnaehana ʻē aʻe

Hana ia ma ka hoʻopaʻa ʻana i ka mea loaʻa ma IL-17. Hoʻokani ke ala IL-17 i ka mumū a pili i ka hoʻomohala ʻana o nā plake psoriasis.

I nā hoʻokolohua hoʻokolohua, ʻoi aku ka nui o nā mea i mālama ʻia me Siliq ma mua o ka poʻe i loaʻa kahi placebo e loaʻa ka ʻili i manaʻo ʻia he maopopo a aneane maopopo.

Lawe ʻia ʻo Siliq ma ke ʻano he injection. Inā kuhikuhi kāu kauka i ka lāʻau, loaʻa iā ʻoe hoʻokahi injection i ka pule no 3 mau pule mua. Ma hope, e loaʻa ʻoe i hoʻokahi injection i kēlā me kēia 2 pule.

E like me nā biologics ʻē aʻe, hoʻonui ʻo Siliq i kāu makaʻi no ka maʻi. He pahu ʻeleʻele hoʻi ka lepili no kēia lāʻau lapaʻau e pili ana i ka nui o ka makaʻu o nā manaʻo suicidal a me ka lawena.

ʻO nā kānaka me ka mōʻaukala o ka hana suicidal a i ʻole ke kaumaha e pono e nānā ʻia i ka wā e lawe ana i ka brodalumab.

Ixekizumab (Taltz)

Ua ʻae ʻia ʻo Ixekizumab (Taltz) ma ka lā ʻo Malaki 2016 e mālama i nā mākua me ka maʻi maʻamau a koʻikoʻi hoʻi i ka maʻi. Hoʻonohonoho ʻia ia no ka poʻe i moho no ka phototherapy, systemic therapy, a i ʻole ʻelua.

Hoʻolālā ʻo Taltz i ka protein IL-17A.

He lāʻau hoʻouka. E loaʻa iā ʻoe i ʻelua kuʻina i kou lā mua, nā kōkō i kēlā me kēia 2 pule no 3 mau mahina e hiki mai ana, a me nā injection i kēlā me kēia 4 mau pule no ke koena o kāu lapaʻau.

Ua hoʻokumu ʻia ka ʻae ma luna o nā hopena o nā noiʻi hoʻokolohua he nui me nā poʻe i komo 3,866. I kēlā mau noi ʻana, ʻo ka hapa nui o ka poʻe e lawe nei i ka lāʻau i loaʻa ka ʻili i maopopo a ʻaneʻane mōakāka paha.

ʻO nā hopena ʻaoʻao maʻamau o Taltz e komo pū:

  • luna maʻi hanu maʻi
  • nā hopena ma ka pūnaewele injection
  • nā maʻi lele

ʻO Biosimilars

ʻAʻole pololei nā kope biosimilar i nā biologics. Akā, huli ʻenekinia huli lākou e hana i nā hopena like e like me nā biologics.

E like me nā lāʻau laulaha, hana ʻia nā biosimilars ke pau ka palapala biologic i ka palapala Sila Nui. ʻO ka maikaʻi o nā biosimilars ke kumu kūʻai pinepine ʻia ma mua o ka huahana kumu.

ʻO Biosimilars no psoriasis ka mea i lalo:

ʻO Biosimilars i adalimumab (Humira)

  • adalimumab-adaz (Hyrimoz)
  • adalimumab-adbm (Cyltezo)
  • adalimumab-afzb (Abrilada)
  • adalimumab-atto (Amjevita)
  • adalimumab-bwwd (Hadlima)

ʻO Biosimilars e etanercept (Enbrel)

  • etanercept-szzs (Erelzi)
  • etanercept-ykro (Eticovo)

ʻO Biosimilars i infliximab (Remicade)

  • infliximab-abda (Renflexis)
  • infliximab-axxq (Avsola)
  • infliximab-dyyb (Inflectra)

ʻO ka Remicade biosimilar Inflectra ʻo ia ka biosimilar psoriasis mua i loaʻa i ka ʻae ʻia o FDA. ʻO ia ma ʻApelila 2016.

ʻO Inflectra lāua ʻo Renflexis, kekahi biosimilar Remicade, kahi wale nō i loaʻa i kēia manawa no ke kūʻai ʻana ma United States. ʻO kēia ke kumu no ka mea ʻo nā patent i mālama ʻia e nā mea hana o nā biologics ʻaʻole e pau.

Nā mālama kumuhana hou

ʻO nā kuʻina kumuhana, a i ʻole nā ​​mea āu e ʻānai ai i kou ʻili, ʻo ia nā lā lapaʻau mua e ʻōlelo ai nā kauka no psoriasis. Hana lākou ma ka hoʻohaʻahaʻa ʻana i ka mumū a me ka hoʻolohi ʻana i ka nui o ka hana o ka ʻili o ka ʻili.

Halobetasol propionate-tazarotene lotion, 0.01% / 0.045% (Duobrii)

I ʻApelila 2019, ua ʻae ka FDA i ka lotion propionate-tazarotene lotion, 0,01 pakeneka / 0,045 pakeneka (Duobrii) no ka hoʻomaʻamaʻa ʻana i ka plake psoriasis i nā mākua.

ʻO Duobrii ka lotion mua e hoʻohui i kahi corticosteroid (halobetasol propionate) me kahi retinoid (tazarotene). Hoʻomaʻemaʻe ka lāʻau anti-inflammatory corticosteroid i nā pā, ʻoiai ʻo ka retinoid a A-i hoʻokumu ʻia ka palena o ka ulu nui o nā ʻili o ka ʻili.

Hoʻohana ʻia ʻo Duobrii i hoʻokahi manawa i ka lā i nā wahi i pili o ka ʻili.

ʻO nā hopena ʻaoʻao nui:

  • ʻeha ma ka pūnaewele noi
  • hūwī
  • folliculitis, a i ʻole nā ​​follicle lauoho i hoʻāʻo ʻia
  • e ʻaʻapo ana i ka ʻili kahi e hamo ai ka wai ʻalona
  • excoriation, a ʻili ʻili paha

Hula Halobetasol propionate, 0.05% (Lexette)

ʻO Halobetasol propionate foam, 0.05 pākēneka kahi corticosteroid kumuhana a ka FDA i ʻae mua ai, ma ke ʻano he generic, i Mei 2018. I ʻApelila 2019, ua loaʻa ia ma lalo o ka inoa Lexette.

Hoʻohana ia e mālama i ka plake psoriasis i nā mākua. ʻO kāna pahuhopu ka hoʻomaʻemaʻe i ka ʻili.

ʻElua mau manawa i ka lā, hoʻopili ʻia ka hua i kahi papa lahilahi a hamo i ka ʻili. Hiki ke hoʻohana ʻia ʻo Lexette a i ʻelua mau pule.

ʻO nā hopena ʻaoʻao maʻamau o Lexette he ʻeha ma ka pūnaewele noi a me ka ʻeha o ke poʻo.

ʻAlika propionate ʻo Halobetasol, 0.01% (Bryhali)

ʻO Halobetasol propionate lotion, 0.01 pākēneka (Bryhali) i ʻae ʻia e ka FDA i Nowemapa 2018. Hoʻolālā ʻia ia no nā mākua me ka psoriasis plaque.

ʻO kekahi o nā ʻōuli e kōkua ia i ka helu ʻana:

  • hoʻomaloʻo
  • flaking
  • pehu
  • kūkulu papa

Hoʻohana ʻia ʻo Bryhali i kēlā me kēia lā. Hiki ke hoʻohana ʻia ka lāʻau lotion a hiki i 8 mau pule.

ʻO nā hopena ʻaoʻao maʻamau e pili pū me:

  • lapalapa ʻana
  • ʻōniu
  • ʻūlili
  • hoʻomaloʻo
  • nā maʻi maʻi hanu o luna
  • kō kō kiʻekiʻe

ʻO Betamethasone dipropionate spray, 0.05% (Sernivo)

I Pepeluali 2016, ua ʻae ka FDA i ka betamethasone dipropionate spray, 0,05 pakeneka (Sernivo). Mālama kēia kumuhana kumuhana akahai a akahai i ka poʻe i piha i ka makahiki 18 a ʻoi.

Kōkua ʻo Sernivo i ka hoʻopakele ʻana i nā ʻōuli o ka psoriasis e like me ka ʻili, ka hili ʻana, a me ka ʻulaʻula.

Pāpī ʻoe i kēia lāʻau corticosteroid ma luna o ka ʻili i ʻelua mau manawa i ka lā a ʻānai mālie iā ia i loko. Hiki ke hoʻohana ʻia a hiki i 4 mau pule.

ʻO nā hopena ʻaoʻao maʻamau ka:

  • ʻūlili
  • lapalapa ʻana
  • ʻōniu
  • ʻeha ma ka pūnaewele noi
  • atrophy ʻili

Nā hoʻoponopono hou no nā keiki

Ua ʻae ʻia kekahi mau lāʻau lapaʻau psoriasis i loaʻa wale no nā mākua i kēia manawa no ka mālama ʻana i nā keiki pū kekahi.

Hulu Calcipotriene, 0.005% (Sorilux)

I ka makahiki 2019, ua hoʻonui ka FDA i kāna mau ʻae no kekahi ʻano wikamina D i kapa ʻia he kalipipipriene hua, 0,005 pakeneka (Sorilux). Hoʻohana ʻia ia no ka mālama ʻana i ka plake psoriasis o ka maʻi poʻo a me ke kino.

I Mei, ua ʻae ʻia ka hoʻohana no nā keiki mai ka makahiki 12 a 17 mau makahiki. ʻO Nowemapa aʻe, ua ʻae ʻia e mālama i ka plake psoriasis o ka maʻi poʻo a me ke kino i nā keiki ma mua o 4 mau makahiki.

Kōkua ʻo Sorilux i ka lohi o ka ulu ʻana o ka ʻili ʻili ma psoriasis. Hoʻohana ʻia kēia hua i nā wahi i hoʻopā ʻia o ka ʻili i ʻelua mau manawa i ka lā a hiki i 8 mau pule. Inā hoʻomaikaʻi ʻole nā ​​ʻōuli ma hope o 8 mau pule, e nīnau i kāu kauka.

ʻO nā hopena ʻaoʻao maʻamau ka ʻulaʻula a me ka ʻeha ma ka pūnaewele noi.

Calcipotriene-betamethasone dipropionate hua, 0.005% / 0.064% (Enstilar)

I Iulai Iulai 2019, ua ʻae ka FDA i ka hua kalipopriot-betamethasone dipropionate, 0.005 pākēneka / 0.064 pākēneka (Enstilar) no ka hoʻohana ʻana i nā ʻōpio ma waena o 12 a me 17 mau makahiki. Hoʻolālā ʻia ia no ka poʻe me ka psoriasis plaque.

Hoʻohaʻahaʻa ʻo Calcipotriene i ka ulu ʻana o ka ʻili, ʻoiai ʻo betamethasone dipropionate e kōkua i ka hoʻoliʻiliʻi o ka mumū.

Hoʻohana ʻia ka hua i kēlā me kēia lā a i ʻehā mau pule.

ʻO nā hopena ʻaoʻao maʻamau e pili pū me:

  • ʻūlili
  • folliculitis
  • hū me nā puʻupuʻu ʻulaʻula a hives paha i hāpai ʻia
  • ʻoi aku ka maikaʻi o psoriasis

Hoʻomaha ʻia ʻo Calcipotriene-betamethasone dipropionate hoʻopau ʻia, 0.005% / 0.064% (Taclonex)

I Iulai Iulai 2019, ua ʻae ʻia ka helu kalipotriene-betamethasone dipropionate topical, 0,005 pakeneka / 0,064 pakeneka (FDA) i ʻae ʻia no ka hoʻohana ʻana i nā keiki he 12 a 17 mau makahiki me ka pākuʻi psoriasis o ke kino.

Ua ʻae ʻia ka FDA e ka wehe ʻana no ke kumuhana no 12- a 17 mau makahiki me ka plaque psoriasis o ka ʻili. ʻO kahi hamo Taclonex i ʻāpono mua ʻia e ka FDA no nā ʻōpio a me nā mākua me ka psoriasis plaque.

Hoʻomoe ʻia ʻo Taclonex topical suspence i kēlā me kēia lā a i 8 mau pule. No nā keiki he 12 a 17 mau makahiki, ʻo ka palena nui o kēlā me kēia pule he 60 gram (g). ʻO ka palena kiʻekiʻe o nā pule hebedoma no 100 mākua.

ʻO nā hopena ʻaoʻao maʻamau e pili pū me:

  • ʻūlili
  • lapalapa ʻana
  • hoʻonāukiuki
  • ʻulaʻula
  • folliculitis

ʻO Ustekinumab (Stelara)

I ʻOkakopa 2017, ua ʻae ka FDA i ustekinumab (Stelara) no nā ʻōpio he 12 mau makahiki a keu. Hiki ke hoʻohana ʻia no ka poʻe ʻōpio me ka psoriasis kaulike a paʻakikī i nā moho no ka phototherapy a i ʻole ka systemic therapy.

Ua hele mai ka ʻae ma hope o kahi noiʻi ma 2015 e ʻike ka hoʻomaʻemaʻe nui ʻana o ka lāʻau i ka ʻili ma hope o 3 mau mahina. Ma nā ʻano ʻili a me ka palekana o ka ʻili, ua like nā hopena me nā mea i ʻike ʻia i nā mākua.

Paʻa ʻo Stelara i nā protein ʻelua i kī i ke kaʻina hana hoʻomeamea, IL-12 a me IL-23.

Hāʻawi ʻia ia ma ke ʻano he subcutaneous injection. Hoʻokumu ʻia ka hana ʻana ma ke kaupaona o ke kino:

  • ʻO nā ʻōpio i kaupaona ma lalo o 60 kilokilo (132 paona) e loaʻa iā 0.75 milligrams (mg) i kēlā me kēia kilokilo o ke kaupaona.
  • ʻO nā ʻōpio i kaupaona ma waena o 60 kg (132 lbs.) A me 100 kg (220 lbs.) Loaʻa i kahi koina 45-mg.
  • ʻO nā ʻōpio i kaupaona ma mua o 100 kg (220 lbs.) Loaʻa iā 90 mg, ʻo ia ka mahele maʻamau no nā mākua o ke kaupaona like.

Hāʻawi ʻia nā mahele hope ʻelua i 4 mau pule kaawale. Ma hope o kēlā, hāʻawi ʻia ka lāʻau i hoʻokahi manawa i kēlā me kēia 3 mahina.

ʻO nā hopena ʻaoʻao maʻamau ka:

  • nā anu a me nā maʻi maʻi hanu ʻē aʻe o luna
  • ʻeha poʻo
  • luhi

Etanercept (Enbrel)

I Nowemapa 2016, ua ʻae ʻo FDA i ka etanercept (Enbrel) e mālama i ka kaulike kaulike a hiki i ka plake koʻikoʻi psoriasis i nā keiki 4 a 17 mau makahiki i moho no ka phototherapy a i ʻole systemic therapy.

Ua ʻae ʻia ʻo Enbrel e mālama i nā mākua me ka plake psoriasis mai 2004 a mālama i nā keiki me ka ʻōpio idiopathic arthritis (JIA) mai ka makahiki 1999.

Hana kēia lāʻau hoʻoheheʻe ʻia e ka hōʻemi ʻana i ka hana o TNF-alpha.

Ua ʻike ʻia kahi noiʻi 2016 ma kahi o 70 mau keiki mai 4 a 17 mau makahiki i ka palekana o Enbrel a hoʻomau i ka hana a hiki i 5 mau makahiki.

I kēlā me kēia pule, loaʻa nā keiki a me nā ʻōpio i ka 0.8 mg o ka lāʻau i kēlā me kēia kilokilo o ko lākou kino kaupaona. ʻO ka mahele lāʻau nui a ko lākou kauka e kuhikuhi ai he 50 mg i kēlā me kēia pule, ʻo ia ka mahele maʻamau no nā mākua.

ʻO nā hopena ʻaoʻao maʻamau nā hopena i ka pūnaewele injection a me nā maʻi respiratory respiratory luna.

Nā mālama ʻē aʻe e kokoke ana i ka ʻāpono

Ke kokoke nei nā lāʻau ʻē aʻe i ka ʻae ʻia o ka FDA.

ʻO Bimekizumab

ʻO Bimekizumab kahi lāʻau biologic i hoʻokomo ʻia e hoʻāʻo ʻia nei ma ke ʻano he lāʻau lapaʻau no ka psque plaque maʻi mau. Hana ia ma ka pale ʻana iā IL-17.

Aia ʻo Bimekizumab i kēia manawa ma ka ʻāpana III. I kēia manawa, ua hōʻike ʻia kahi noiʻi e palekana a maikaʻi.

I ka hoʻokolokolo hoʻokolohua BE SURE, ʻoi aku ka maikaʻi o ka bimekizumab ma mua o adalimumab (Humira) i ke kōkua ʻana i ka poʻe e loaʻa ma kahi o 90 ka nui o ka hoʻomaikaʻi i nā helu i hoʻohana ʻia e ana i ka nui o ka maʻi.

Calcipotriene-betamethasone dipropionate cream, 0.005% / 0.064% (Wynzora)

I ka makahiki 2019, ua waiho ʻia kahi noi lāʻau hou i ka FDA no Wynzora. ʻO Wynzora kahi kalima i kēlā me kēia lā e hoʻohui i ka calculipotriene a me ka betamethasone dipropionate.

I ke kaʻina o ka mahele III, ua ʻoi aku ka maikaʻi o Wynzora i ka hoʻomaʻemaʻe ʻana i ka ʻili ma hope o 8 mau pule ma mua o ka hoʻomaha a me ka kalima Taclonex.

Loaʻa ʻo Wynzora i ke keu ʻo ka nongreasy, ka mea i ʻike ʻia e nā mea hoʻopaʻa haʻawina ua ʻoi aku ka maʻalahi.

Mea kāohi iā JAK

ʻO nā mea kāohi JAK kahi hui ʻē aʻe o ka hoʻololi ʻana i ka maʻi. Hana lākou ma ka ʻimi ʻana i nā ala e kōkua i ke kino e hana i nā protein inflammative.

Hoʻohana ʻia lākou e mālama:

  • arthritis psoriatic
  • rumatika
  • ulcerative colitis

Aia kekahi mau mea i ka mahele II a me ka pae III e hoʻāʻo no ka maʻi maʻamau a koʻikoʻi. Ke aʻo ʻia nei no ka psoriasis ʻo ia nā lāʻau lapaʻau waha tofacitinib (Xeljanz), baricitinib (Olumiant), a me abrocitinib. Ke hoʻokolokolo ʻia nei nō hoʻi kahi mea kāohi JAK kumuhana.

I kēia manawa, ua loaʻa nā noiʻi i nā mea kāohi iā JAK e maikaʻi no ka psoriasis. Pili lākou e like me ka palekana e like me nā lāʻau biologic e kū nei. ʻO kahi pōmaikaʻi ke hele mai lākou i kahi ʻano pila a ʻaʻohe pono e hāʻawi ʻia e like me nā injection.

ʻO nā haʻawina i hana ʻia i kēia manawa he manawa pōkole ia. Pono e noiʻi hou e ʻike inā hoʻomau ka maikaʻi o nā mea kāohi ʻo JAK i nā manawa lōʻihi.

Lawe aku

Ke waiho nei i ka ʻike e pili ana i nā koho hou loa no ka mālama ʻana i ka psoriasis he mea nui i ka mālama ʻana i kāu kūlana.

ʻAʻole kahi hoʻokahi-nui-fits-all therapy no psoriasis. Maliʻa paha e hoʻāʻo ʻoe i nā ʻano lāʻau like ʻole ma mua o ka loaʻa ʻana o kahi mea kūpono loa iā ʻoe a ʻaʻole ia e kumu i nā hopena ʻaoʻao.

Loaʻa nā mea hou i ka psoriasis i nā manawa āpau. E hōʻoia e kamaʻilio me kāu kauka e pili ana i nā koho lapaʻau hou.

HoʻOmaopopo Mākou IāʻOe E Heluhelu

Mālama i kāu hui kuli hou
Kino PaʻA

Mālama i kāu hui kuli hou

Ma hope o kou hoʻokuli ʻana i ke kuli, pono ʻoe e akahele e pili ana i kou neʻe ʻana i kou kuli, ʻo ia hoʻi no nā mahina mua ma hope o ke kahakaha ʻana.I ka manawa, hiki iā ʻoe ke hoʻi i kāu pae o ka ...
Hōʻike wahi mononucleosis
Kino PaʻA

Hōʻike wahi mononucleosis

Nānā ka hōʻike wahi mononucleo i no 2 mau mea ʻino i loko o ke koko. Hōʻike kēia mau mea ʻino i ka wā a ma hope paha o ka maʻi me ka maʻi viru i kumu i ka mononucleo i , a i ʻole mono.Pono kahi laʻana...